17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts

Grossman, Michael, D.P.M.

Status and phase: Unknown; Phase 4

Conditions: Warts

Treatments: Drug: 17% Salicylate with ethyl pyruvate; Drug: Salicylates

Study type: Interventional

Funder types: Other

Identifiers

NCT01712295

R12-3128

Details and patient eligibility

About

Plantar warts on the sole of the foot are among the most common warts seen in podiatry clinics. Some patients are readily cured by simple standard of care treatments that include wart debridement (trimming or excision) and application of 17% salicylate (commercially known as Compound W)or by other treatments that may be painful and affect mobility. No treatment is consistently effective and most patients fail treatment multiple times.

Ethyl pyruvate (EP)is a common food additive noted to be 'generally regarded as safe' that may improve the activity of salicylate in wart treatment by improving the ability to penetrate and/or persist in the skin. The use of 17% salicylate with the addition of EP may improve cures of common foot plantar warts in subjects who also be receiving other standard-of-care treatment.

Enrollment: 100 estimated patients

Sex: All

Ages: 12 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• evidence of skin plantar wart(s)

Exclusion criteria

• iodine allergy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

100 participants in 2 patient groups

17% Salicylate with Ethyl Pyruvate

Experimental group

Description:

Subjects with plantar wart(s) will apply the product to warts twice a day for up to 16 weeks.

Treatment:

Drug: 17% Salicylate with ethyl pyruvate

17% salicylate

Active Comparator group

Description:

subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks

Treatment:

Drug: Salicylates